{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:05:01Z","timestamp":1790791501962,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CORPG3H0391"],"award-info":[{"award-number":["CORPG3H0391"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW107-TDU-B-212-113005"],"award-info":[{"award-number":["MOHW107-TDU-B-212-113005"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW108-TDU-B-212-113005"],"award-info":[{"award-number":["MOHW108-TDU-B-212-113005"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW109-TDU-B-212-114005"],"award-info":[{"award-number":["MOHW109-TDU-B-212-114005"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bj.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T01:05:43Z","timestamp":1634346343000},"page":"821-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer"],"prefix":"10.1016","volume":"45","author":[{"given":"Wei-Chun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei-Jean","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Bin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Gen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Hsin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Hsueh","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bj.2021.10.003_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.bj.2021.10.003_bib2","author":"Taiwan DoH"},{"key":"10.1016\/j.bj.2021.10.003_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2021.10.003_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2307\/3576564","article-title":"DNA lesions in hyperthermic cell killing: effects of thermotolerance, procaine, and erythritol","volume":"106","author":"Jorritsma","year":"1986","journal-title":"Radiat Res"},{"key":"10.1016\/j.bj.2021.10.003_bib6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/bi00455a013","article-title":"Thermal denaturation of the Ca2(+)-ATPase of sarcoplasmic reticulum reveals two thermodynamically independent domains","volume":"29","author":"Lepock","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.bj.2021.10.003_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/026567399285765","article-title":"For the clinical application of thermochemotherapy given at mild temperatures","volume":"15","author":"Urano","year":"1999","journal-title":"Int J Hyperther"},{"key":"10.1016\/j.bj.2021.10.003_bib8","series-title":"Thermoradiotherapy and thermochemotherapy: biology, physiology, physics","first-page":"361","article-title":"Recent trends in noninvasive thermal control","author":"Bolomey","year":"1995"},{"key":"10.1016\/j.bj.2021.10.003_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2005.12.006","article-title":"Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma","volume":"100","author":"Trimble","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1245\/s10434-014-4049-z","article-title":"The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction","volume":"22","author":"Cascales-Campos","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib12","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1245\/s10434-014-3693-7","article-title":"Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study","volume":"21","author":"Le Brun","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jso.23688","article-title":"Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study","volume":"110","author":"Safra","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0959-8049(98)00375-X","article-title":"Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment","volume":"35","author":"Berthet","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bj.2021.10.003_bib15","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s002800051093","article-title":"Successful management of microscopic residual disease in large bowel cancer","volume":"43","author":"Sugarbaker","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bj.2021.10.003_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bj.2021.10.003_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bj.2021.10.003_bib18","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2018"},{"key":"10.1016\/j.bj.2021.10.003_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/gyno.2002.6859","article-title":"Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer","volume":"88","author":"Havrilesky","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib20","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib22","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2021.10.003_bib23","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2021.10.003_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tjog.2019.10.003","article-title":"Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer","volume":"59","author":"Chen","year":"2020","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.bj.2021.10.003_bib26","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1200\/JCO.2020.38.15_suppl.6000","article-title":"Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-ov20","volume":"38","author":"Bois","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib27","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2020.38.15_suppl.6001","article-title":"A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1\/SGOG-OV2","volume":"38","author":"Zang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejogrb.2014.05.018","article-title":"Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients","volume":"179","author":"Cascales-Campos","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bj.2021.10.003_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3802\/jgo.2015.26.1.54","article-title":"Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study","volume":"26","author":"Coccolini","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib30","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib31","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1471-0528.2011.03207.x","article-title":"Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study","volume":"119","author":"Deraco","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.bj.2021.10.003_bib32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1245\/s10434-015-4991-4","article-title":"Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: a single-center comparative analysis","volume":"23","author":"Baiocchi","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejso.2015.11.006","article-title":"Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center","volume":"42","author":"Munoz-Casares","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1245\/s10434-016-5686-1","article-title":"Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases","volume":"24","author":"Di Giorgio","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/02656736.2018.1423708","article-title":"Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy","volume":"34","author":"Arjona-Sanchez","year":"2018","journal-title":"Int J Hyperther"},{"key":"10.1016\/j.bj.2021.10.003_bib37","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.3802\/jgo.2018.29.e53","article-title":"Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study","volume":"29","author":"Ceresoli","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.bj.2021.10.003_bib39","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bj.2021.10.003_bib40","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results","volume":"135","author":"Chua","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bj.2021.10.003_bib41","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/02656736.2017.1337238","article-title":"Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia","volume":"34","author":"Wang","year":"2018","journal-title":"Int J Hyperthermia"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417021001372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417021001372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:12:43Z","timestamp":1762420363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417021001372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2319417021001372"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2021.10.003","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chang Gung University. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}